Asthma, airway biology, and allergic rhinitis in AJRCCM 2000

American Journal of Respiratory and Critical Care Medicine

Volumn 164, Issue 9, 2001, Pages 1559-1580

  Tobin, Martin J ^a,b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; SALBUTAMOL; SALMETEROL; TERBUTALINE; TRIAMCINOLONE; ZILEUTON;

ALLERGIC RHINITIS; ASTHMA; BRONCHITIS; BRONCHOSPASM; CLINICAL TRIAL; DRUG MECHANISM; DRUG MEGADOSE; DYSPNEA; EOSINOPHILIA; EXERCISE INDUCED ASTHMA; HUMAN; OCCUPATIONAL ASTHMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK FACTOR;

EID: 0035508429     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.164.9.2108114     Document Type: Review

References (234)

1. Association of β2-adrenoreceptor variants with bronchial hyperresponsiveness
2. Association study of the chromosomal region containing the FCER2 gene suggests it has a regulatory role in atopic disorders
3. A common FCER1B gene promoter polymorphism influences total serum IgE levels in a Japanese population
4. Relationships of active and passive smoking to total IgE in adults of the Epidemiological Study of the Genetics and Environment of Asthma, bronchial hyperresponsiveness, and atopy (EGEA)
5. Polymorphism at the glutathione S-transferase GSTP1 locus. A new marker for bronchial hyperresponsiveness and asthma
6. Independent inheritance of serum immunoglobulin E concentrations and airway responsiveness
7. 2-Adrenergic receptor Arg16/Arg16 genotype is associated with reduced lung function, but not with asthma, in the Hutterites
8. Linkage analysis of markers on chromosome 11q13 with asthma and atopy in a United Kingdom population
9. Evidence for genetic associations between asthma, atopy, and bronchial hyperresponsiveness: A study
10. Association between plasma CC16 levels, the A38G polymorphism, and asthma
11. Exhaled nitric oxide in patients with asthma: Association with NOS1 genotype
12. Familial aggregation of bronchodilator response: A community-based study
13. 2-adrenergic receptor on the response to regular use of albuterol in asthma
14. 2-adrenergic receptor gene and desensitization in human airway smooth muscle
15. Application of an algorithm for the diagnosis of asthma in Chinese families: Limitations and alternatives for the phenotypic assessment of asthma in family-based genetic studies
16. Genome screen for asthma and related phenotypes in the French EGEA study
17. Interactions between corticosteroids and beta-adrenergic agonists in asthma disease induction, progression, and exacerbation
18. 2-Adrenergic receptor pharmacogenetics
19. The genetics of asthma. The important questions
20. What determines asthma phenotype? Is it the interaction between allergy and the smooth muscle?
21. What determines asthma phenotype? Respiratory infections and asthma
22. Asthma mortality in U.S. Hispanics of Mexican, Puerto Rican, and Cuban heritage, 1990-1995
23. Differences in incidence of reported asthma related to age in men and women. A retrospective analysis of the data of the European Respiratory Health Survey
24. Relation between phase of menstrual cycle and emergency department visits for acute asthma
25. Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8
26. Lymphocytes migrate from the blood into the bronchoalveolar lavage and lung parenchyma in the asthma model of the brown Norway rat
27. CD23 exhibits negative regulatory effects on allergic sensitization and airway hyperresponsiveness
28. Synthetic oligodeoxynucleotides inhibit IgE induction in human lymphocytes
29. House dust mite-induced airway changes in hu-SCID mice
30. Induced sputum cell counts in healthy adults
31. Induced sputum cellularity. Reference values and distribution in normal volunteers
32. The relationship between airways inflammation and asthma severity
33. Prostaglandin H synthase 2 expression in airway cells from patients with asthma and chronic obstructive pulmonary disease
34. Increased numbers of both airway basophils and mast cells in sputum after allergen inhalation challenge of atopic asthmatics
35. Interleukin 16 and T-cell chemoattractant activity in bronchoalveolar lavage 24 hours after allergen challenge in asthma
36. Monocyte chemoattractant protein (MCP)-4 expression in the airways of patients with asthma. Induction in epithelial cells and mononuclear cells by proinflammatory cytokines
37. Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma. Influence of inhaled corticosteroids
38. Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group
39. + T cells in asthma
40. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals
41. 1-acid glycoprotein in asthma. A correlation with lung function and inflammatory parameters
42. Endogenous airway acidification. Implications for asthma pathophysiology
43. No waiting to exhale in asthma
44. Changes in sputum eosinophils predict loss of asthma control
45. Airway nitric oxide diffusion in asthma: Role in pulmonary function and bronchial responsiveness
46. Exhaled nitric oxide following repeated spirometry or repeated plethysmography in healthy individuals
47. Adolescents in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and bronchial hyperresponsiveness
48. 4 and methacholine inhalation in patients with asthma
49. Increased nitrotyrosine in exhaled breath condensate of patients with asthma
50. Elevation of exhaled ethane concentration in asthma
51. Expression of heme oxygenase isoenzymes 1 and 2 in normal and asthmatic airways: Effect of inhaled corticosteroids
52. 2 on interleukin-1 beta-induced cyclooxygenase-2 expression in human airway smooth-muscle cells
53. New aspects of degranulation and fates of airway mucosal eosinophils
54. Key factors in the development of asthma: Atopy
55. Endogenous inhibitory mechanisms in asthma
56. Why does airway inflammation persist? Is it failure to treat early?
57. Why does airway inflammation persist? Is it leukotrienes?
58. Introduction
59. Prenatal sensitization in a mouse model
60. Gene knockout models of asthma
61. The road to the production of IgE is long and winding
62. Atopic allergy: A failure of antigen-presenting cells to properly polarize helper T cells?
63. Regulation of interleukin 4 gene transcription: Alterations in atopic disease?
64. One cytokine, two isotypes: A Trojan horse, Pandora's box, and an evolving paradigm
65. Primary sensitization to inhalant allergens
66. Viruses and atopic sensitization in the first years of life
67. Immune parameters in high-risk atopic individuals during early childhood
68. Perinatal events in relation to sensitization in the human
69. Viral infections and childhood asthma
70. Bronchial epithelium as a key regulator of airway allergen sensitization and remodeling in asthma
71. The genetics of atopy and airway hyperresponsiveness
72. Specific IgE and IgG responses in atopic versus non-atopic subjects
73. Determinants of clinical allergic disease. The relevance of indoor allergens to the increase in asthma
74. Atopy as a risk factor for chronic obstructive pulmonary disease: Epidemiological evidence
75. Purpose of the conference
76. Antigen processing, presentation, and immunomodulation
77. Innate immune system damage in human immunodeficiency virus type 1 infection. Implications for acquired immunity and vaccine design
78. Antigen-presenting cells. Experimental and clinical studies of dendritic cells
79. Antigen presentation in the lung
80. Regulation of helper T cell differentiation and recruitment in airway inflammation
81. Gammadelta cells and the regulation of mucosal immune responses
82. Costimulation of T cells
83. Immunological tolerance to inhaled antigen
84. Oral tolerance
85. Biotherapeutic targets for the treatment of allergic airway disease
86. Control of experimental inflammatory bowel disease by regulatory T cells
87. Antigen presentation and DNA vaccines
88. Gene delivery to the corneal endothelium
89. Prolonged allergen exposure induces structural airway changes in sensitized rats
90. + T cells in αβ-T cell receptor transgenic mice
91. Inhibitors of tyrosine kinase signaling cascade attenuated antigen challenge of guinea-pig airways in vitro
92. 1 blocks antigen-induced airway responses and inflammation in experimental asthma in sheep
93. Cyclooxygenase inhibition increases interleukin 5 and interleukin 13 production and airway hyperresponsiveness in allergic mice
94. CD8 depletion-induced late airway response is characterized by eosinophilia, increased eotaxin, and decreased IFN-gamma expression in rats
95. Timing of administration of anti-VLA-4 differentiates airway hyperresponsiveness in the central and peripheral airways in mice
96. Pulmonary vascular congestion selectively potentiates airway responsiveness in piglets
97. Resistance of very young mice to inhaled allergen sensitization is overcome by coexposure to an air-pollutant aerosol
98. Correlation between nuclear factor-κB activity in bronchial brushing samples and lung dysfunction in an animal model of asthma
99. Bronchial responsiveness among inbred mouse strains. Role of airway smooth-muscle shortening velocity
100. Virusand bradykinin-induced airway hyperresponsiveness in guinea pigs
101. Presence and bronchomotor activity of protease-activated receptor-2 in guinea pig airways
102. Effect of eotaxin and platelet-activating factor on airway inflammation and hyperresponsiveness in guinea pigs in vivo
103. Heparin inhibits eicosanoid metabolism and hyperventilation-induced bronchoconstriction in dogs
104. Mechanisms of endotoxin-induced airway and pulmonary vascular hyperreactivity in mice
105. Smooth-muscle myosin light-chain kinase content is increased in human sensitized airways
106. PAF-induced RANTES production by human airway smooth muscle cells requires both p38 MAP kinase and Erk
107. Human isolated bronchial smooth muscle contains functional ryanodine/caffeine-sensitive Ca-release channels
108. The production of extracellular matrix proteins by human passively sensitized airway smooth-muscle cells in culture: The effect of beclomethasone
109. Epithelial desquamation in asthma: Artifact or pathology?
110. Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics
111. Predictors of late asthmatic response. Logistic regression and classification tree analyses
112. Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses
113. 2 in airways of subjects with asthma
114. Attenuation of the allergen-induced late asthmatic reaction by cyclosporin A is associated with inhibition of bronchial eosinophils, interleukin-5, granulocyte macrophage colony-stimulating factor, and eotaxin
115. Increased matrix metalloproteinase-9 in the airway after allergen challenge
116. 2-receptor genotype
117. Guidelines for methacholine and exercise challenge testing - 1999. Official statement of the American Thoracic Society (adopted by the ATS Board of Directors, July 1999)
118. Airway hyperresponsiveness in elite athletes
119. Evidence of airway inflammation and remodeling in ski athletes with and without bronchial hyperresponsiveness to methacholine
120. Nedocromil sodium inhibits responsiveness to inhaled mannitol in asthmatic subjects
121. Inhalant corticosteroids inhibit hyperosmolarity-induced, and cooling and rewarming-induced interleukin-8 and RANTES production by human bronchial epithelial cells
122. Exercise-induced bronchoconstriction does not cause eosinophilic airway inflammation or airway hyperresponsiveness in subjects with asthma
123. Pulmonary capillary blood volume in hyperpnea-induced bronchospasm
124. Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma
125. What is the relationship between airway hyperresponsiveness and atopy?
126. Airway smooth muscle in asthma. Perturbed equilibria of myosin binding
127. Deciphering the homeokinetic code of airway smooth muscle
128. What makes the airways contract abnormally? Is it inflammation?
129. Airway remodeling in asthma. Unanswered questions
130. Airway hyperresponsiveness to cigarette smoke in ovalbumin-sensitized guinea pigs
131. 2 enhances chemical and mechanical sensitiveness of pulmonary C fibers in the rat
132. Antigen inhalation unmasks NK-2 tachykinin receptor-mediated responses in vagal afferents
133. Toluene diisocyanate enhances substance P in sensory neurons innervating the nasal mucosa
134. Nerve growth factor-induced phenotypic switch in guinea pig airway sensory neurons
135. Responses of tracheobronchial receptors to inhaled furosemide in anesthetized rats
136. Dichotomy between neurokinin receptor actions in modulating allergic airway responses in an animal model of helper T cell type 2 cytokine-associated inflammation
137. Trypsin-induced, neurokinin-mediated contraction of guinea pig bronchus
138. Deep inspiration-induced bronchoprotection is stronger than bronchodilation
139. Delayed distension of contracted airways with lung inflation in vivo
140. Potential mechanism of hyperresponsive airways
141. Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma
142. Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma
143. Increase in perforin-positive peripheral blood lymphocytes in extrinsic and intrinsic asthma
144. Effects of cool, dry air stimulation on peripheral lung mechanics in asthma
145. Airway wall thickness in asthma assessed by computed tomography. Relation to clinical indices
146. Airway narrowing in healthy humans inhaling methacholine without deep inspirations demonstrated by HRCT
147. An analysis algorithm for measuring airway lumen and wall areas from high-resolution computed tomographic data
148. Central airways behave more stiffly during forced expiration in patients with asthma
149. Unsuspected pseudophysiologic emphysema in chronic persistent asthma
150. Recurrent exacerbations in severe asthma are associated with enhanced airway closure during stable episodes
151. Asthma. From bronchoconstriction to airways inflammation and remodeling
152. The risk of myocardial infarction associated with inhaled β-adrenoceptor agonists
153. Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor κB in asthma
154. Transcriptional potencies of inhaled glucocorticoids
155. Inhaled budesonide decreases airway inflammatory response to allergen
156. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification
157. Lung deposition of inhaled drugs increases with age
158. Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function
159. The effects of inhaled budesonide on circulating eosinophil progenitors and their expression of cytokines after allergen challenge in subjects with atopic asthma
160. Glucocorticoid receptor alpha and beta in glucocorticoid dependent asthma
161. Is there a role for glucocorticoid receptor beta in glucocorticoid-dependent asthmatics?
162. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department
163. Muscarinic control of histamine release from airways. Inhibitory M1-receptors in human bronchi but absence in rat trachea
164. Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics
165. Leukotrienes as targets for treatment of asthma and other diseases. Current basic and clinical research
166. The discovery of the leukotrienes
167. From bench to bedside. The hurdles of discovering a new leukotriene receptor antagonist
168. The molecular biology and regulation of 5-lipoxygenase
169. Leukotriene C4 synthase. A pivotal enzyme in the biosynthesis of the cysteinyl leukotrienes
170. Membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG). A widespread protein superfamily
171. Structure, function, and regulation of leukotriene A4 hydrolase
172. Phospholipase A2 in eicosanoid generation
173. Intracellular compartmentalization of leukotriene biosynthesis
174. Pharmacological characterization of leukotriene receptors
175. Binding to cysteinyl-leukotriene receptors
176. Leukotriene B4 receptor. Cloning and intracellular signaling
177. Cloning of a novel chemoattractant receptor activated by leukotriene B4 and used by human immunodeficiency virus type 1 to infect CD4-positive immune cells. A therapeutic connection to asthma?
178. The role of leukotrienes in the regulation of tone and responsiveness in isolated human airways
179. Leukotriene bronchoconstriction induced by allergen and exercise
180. Effects of antileukotrienes in the treatment of asthma
181. Genetic variations in the 5-lipoxygenase core promoter. Description and functional implications
182. The metabolism of leukotriene B4 in Lewis lung carcinoma porcine kidney cells
183. Adenosine, a potent natural suppressor of arachidonic acid release and leukotriene biosynthesis in human neutrophils
184. Formation of endogenous "antiinflammatory" lipid mediators by transcellular biosynthesis. Lipoxins and aspirin-triggered lipoxins inhibit neutrophil recruitment and vascular permeability
185. Measurement of leukotrienes in humans
186. Functional studies of leukotriene receptors in vascular tissues
187. Leukotrienes in cardiovascular diseases
188. Interactions between leukotrienes and other inflammatory mediators/modulators in the microvasculature
189. 5-Lipoxygenase and leukotrienes. Transgenic mouse and nuclear targeting studies
190. Role of leukotrienes in bronchial hyperresponsiveness and cellular responses in airways
191. Leukotrienes in rhinitis
192. Treatment of aspirin-intolerant asthma with antileukotrienes
193. Genetic mechanisms in aspirin-induced asthma
194. Antileukotriene therapy. Future directions
195. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma
196. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma
197. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma
198. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids
199. Effects of budesonide and formoterol on eosinophil activation induced by human lung fibroblasts
200. Proceedings of the ATS workshop on refractory asthma: Current understanding, recommendations, and unanswered questions
201. Airway - Parenchyma uncoupling in nocturnal asthma
202. Spontaneous gastroesophageal reflux and airway patency during the night in adult asthmatics
203. The prevalence of gastroesophageal reflux in asthma patients without reflux symptoms
204. The airway longitudinal elastic fiber network and mucosal folding in patients with asthma
205. Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: Clinical and biologic significance
206. CC chemokines and interleukin-5 in bronchial lavage fluid from patients with status asthmaticus. Potential implication in eosinophil recruitment
207. The effect of age and duration of disease on airway structure in fatal asthma
208. Quality of dyspnea in bronchoconstriction differs from external resistive loads
209. Symptom perception and respiratory sensation in asthma
210. Symptoms, quality of life, and health service contact among young adults with mild asthma
211. Measuring asthma control. Clinic questionnaire or daily diary?
212. Duration of asthma and physiologic outcomes in elderly nonsmokers
213. Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma
214. Long-term follow-up of hexamethylene diisocyanate-, diphenylmethane diisocyanate-, and toluene diisocyanate-induced asthma
215. Identification of human lung and skin proteins conjugated with hexamethylene diisocyanate in vitro and in vivo
216. Individual characteristics and quitting in apprentices exposed to high-molecular-weight agents
217. Respiratory symptoms of obstructive lung disease in European crop farmers
218. Occupational asthma in adults in six Canadian communities
219. Hospitalization among workers compensated for occupational asthma
220. Incidence and determinants of IgE-mediated sensitization in apprentices. A prospective study
221. Persistent specific bronchial reactivity to occupational agents in workers with normal non-specific bronchial reactivity
222. Onset and remission of allergic rhinitis and asthma and the relationship with atopic sensitization and smoking
223. Neutrophil-dependent and neutrophil-independent alterations in the nasal epithelium of ozone-exposed rats
224. Quality of life in allergic rhinitis and asthma. A population-based study of young adults
225. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients
226. Nerve growth factor expression and release in allergic inflammatory disease of the upper airways
227. A mechanism of antigen-induced mucus production in nasal epithelium of sensitized rats. A comparison with lipopolysaccharide-induced mucus production
228. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients
229. Immediate effect of topical budesonide on allergen challenge-induced nasal mucosal fluid levels of granulocyte-macrophage colony-stimulating factor and interleukin-5
230. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection
231. Ipratropium bromide increases the ability of the nose to warm and humidify air
232. Long-term follow-up of pulmonary function in patients with nasal polyposis
233. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness
234. Antiasthmatic effects of mediator blockade versus topical corticosteroids in allergic rhinitis and asthma